Wells Fargo
MRVI icon

Wells Fargo’s Maravai LifeSciences MRVI Stock Holding History

Wells Fargo’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Buy
94,967
+53,176
+127% +$230K ﹤0.01% 4499
2026
Q1 		$118K Sell
41,791
-81,243
-66% -$275K ﹤0.01% 5014
2025
Q4 		$400K Buy
123,034
+38,743
+46% +$130K ﹤0.01% 4644
2025
Q3 		$242K Buy
84,291
+5,054
+6% +$12.9K ﹤0.01% 4826
2025
Q2 		$191K Buy
79,237
+25,388
+47% +$53.4K ﹤0.01% 4800
2025
Q1 		$119K Buy
53,849
+1,164
+2% +$4.6K ﹤0.01% 5009
2024
Q4 		$287K Buy
52,685
+15,001
+40% +$96.5K ﹤0.01% 4562
2024
Q3 		$313K Sell
37,684
-1,786
-5% -$15.4K ﹤0.01% 4287
2024
Q2 		$283K Buy
39,470
+31,176
+376% +$269K ﹤0.01% 4283
2024
Q1 		$71.9K Sell
8,294
-1,209
-13% -$8.18K ﹤0.01% 5080
2023
Q4 		$62.2K Sell
9,503
-20,535
-68% -$133K ﹤0.01% 5188
2023
Q3 		$300K Sell
30,038
-220
-0.7% -$2.42K ﹤0.01% 4096
2023
Q2 		$376K Sell
30,258
-2,308
-7% -$31.2K ﹤0.01% 4150
2023
Q1 		$456K Buy
32,566
+188
+0.6% +$2.7K ﹤0.01% 3911
2022
Q4 		$463K Buy
32,378
+3,925
+14% +$61.8K ﹤0.01% 3688
2022
Q3 		$727K Buy
28,453
+233
+0.8% +$5.85K ﹤0.01% 3443
2022
Q2 		$801K Sell
28,220
-34,130
-55% -$1.08M ﹤0.01% 3436
2022
Q1 		$2.2M Sell
62,350
-43,900
-41% -$1.47M ﹤0.01% 3208
2021
Q4 		$4.45M Sell
106,250
-220,542
-67% -$8.93M ﹤0.01% 2691
2021
Q3 		$16M Buy
326,792
+234,785
+255% +$11.5M ﹤0.01% 1833
2021
Q2 		$3.84M Sell
92,007
-5,293
-5% -$205K ﹤0.01% 3101
2021
Q1 		$3.47M Buy
97,300
+30,279
+45% +$1M ﹤0.01% 3197
2020
Q4 		$1.88M Buy
+67,021
New +$1.87M ﹤0.01% 3544

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Wells Fargo's MRVI Position: Q2 2026 in Review

Wells Fargo increased its Maravai LifeSciences (MRVI) stake by 127% in Q2 2026, buying an estimated $230K and bringing the position to 94,967 shares worth $593K. The position accounts for ﹤0.01% of the portfolio, ranked #4499.

Wells Fargo first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $16M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Wells Fargo held 94,967 shares of Maravai LifeSciences worth $593K as of Q2 2026.
  • Wells Fargo bought 53,176 Maravai LifeSciences shares in Q2 2026, an estimated $230K.
  • Maravai LifeSciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4499 holding.
  • Wells Fargo first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Wells Fargo's Maravai LifeSciences position peaked at $16M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.